Seasonal changes may influence the efficacy of vaccination against diabetes

The development of a medicine for patients with type 1 diabetes mellitus, based on autoantigen GAD65, received a setback following crucial clinical phase 3 trials that failed to show significant effects. One possible explanation may be seasonal variations in the immune system, claim those responsible for the study that was published in the New England Journal of Medicine (NEJM).

At the onset of , the attacks the insulin-producing pancreatic beta-cells. In conjunction with this development are often directed against different proteins/antigens in the beta-cells. The GAD65 is such an antigen, an enzyme typically present in the brain, however its function in the beta-cells is as yet unknown.

Led by Johnny Ludvigsson, Professor Emeritus of at Linköping University, clinical trials were conducted on the treatment with alum-formulated GAD65 (GAD-alum) for patients with recent-onset mellitus. Three years ago, researchers showed in a phase 2 trial that this type of vaccination could retard the degradation of beta-cells. At a four-year follow-up it was established that C-peptide (a measure of endogenous production) was significantly higher in patients who had fallen ill less than six months before the start of the study, compared to that of a control group.

For the phase 3 trial, 334 patients 10 to 20 of age, with type 1 diabetes were recruited. Within three months after diagnosis, patients were randomly assigned to receive one of three study treatments:

  • Four doses of GAD-alum
  • Two doses of GAD-alum followed by two doses of placebo
  • Four doses of placebo
The primary outcome was the change in C-peptide levels 15 months after beginning the treatment. The results showed a positive trend but no significant effect.

The authors of the article in this week's edition of NEJM ask the question: "Why did this phase 3 study show a lack of efficacy, in contrast to our earlier phase 2 study?"

in the immune system may play a role and have been proposed as one possible explanation. When the material is broken down into subgroups, it appears that the treatment had significant effect among those patients who received their first GAD-alum dose during March or April, which was the period when all patients in the phase 2 trial were vaccinated.

Another discrepancy that may have been significant for the results was that the phase 3 study coincided with the outbreak of the swine influenza epidemic, which led to widespread vaccination. The diabetic patients who were not vaccinated against influenza within 150 days responded better to the GAD-alum treatment than the others in the study. Additional factors affecting the results can be related to age and gender. The effects were significant for boys in the large European trial.

The authors write that treatment for type 1 diabetes will probably be based on knowledge gained from this and other studies of single agents or combination therapies. Further analyses are under way addressing, partly the results following a longer follow-up than 15 months, and partly how the immune system responds.

"We have not given up, rather we still believe that the GAD-alum may prove to be an important part of both future prevention and treatment of type 1 diabetes," says Johnny Ludvigsson.

More information: GAD 65 antigen therapy in recently diagnosed type 1 diabetes mellitus by Ludvigsson et al. New England Journal of Medicine 366:5, 2 February 2012.

add to favorites email to friend print save as pdf

Related Stories

Still hope for GAD diabetes vaccine

Jun 22, 2011

Despite the disappointing results in trying to treat children suffering from type 1 diabetes with the GAD vaccine, the treatment has not been written off entirely. DIAPREV-IT, the study in which healthy high-risk children ...

Diabetes vaccine stumbles at second hurdle

Jun 27, 2011

An experimental vaccine to prevent progression of Type 1 diabetes failed at the second step of the three-phase trial process, doctors said on Monday in a study reported online by The Lancet.

Promising results of Phase I diabetes trial announced

Jun 26, 2011

Promising results of the Phase I clinical trial of the generic drug BCG (bacillus Calmette-Guerin) to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego. ...

Recommended for you

Screening for diabetes at dental visits using oral blood

14 hours ago

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not ...

CBT, sertraline insufficient in diabetes and depression

15 hours ago

(HealthDay)—For patients with diabetes and depression, improvements in depression are seen with cognitive behavioral therapy (CBT) or sertraline, with a significant advantage for sertraline, but glycemic ...

Early signs in young children predict type 1 diabetes

21 hours ago

New research shows that it is possible to predict the development of type 1 diabetes. By measuring the presence of autoantibodies in the blood, it is possible to detect whether the immune system has begun to break down the ...

Daily menu plan reduces blood sugar significantly

Feb 25, 2015

A large group of people with diabetes who followed a menu plan created by University of Alberta nutrition researchers for just three months significantly reduced their blood sugar levels.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.